Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 10 of 34

TitleReference numberPublishedLast updated
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1015
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841

Results per page

  1. 10
  2. 25
  3. 50
  4. All